• Privacy Policy
  • Contact Us
Search
  • Overview
    • About EOM
    • Relentless Science
    • Our Focus
    • EOM Pipeline
    • Clinical Trials
    • News & Media
    • Investors
      • Overview
      • Why Invest
      • News
      • Events & Presentations
      • Stock Info
        • Stock Quote
        • Stock Chart
        • Historical Stock Quote
        • Investment Calculator
      • Financials
        • SEC Filings
      • Governance
        • Executive Management
        • Board of Directors
        • Governance Documents
      • Resources
        • Investor FAQs
        • Information Request Form
        • Investor Contacts
        • Investor Email Alerts
Skip to main content
Company Logo

Powering Relentless Science™

Company Logo

Powering Relentless Science™

  • Overview
    • About EOM
    • Relentless Science
    • Our Focus
    • EOM Pipeline
    • Clinical Trials
    • News & Media
    • Investors
      • Overview
      • Why Invest
      • News
      • Events & Presentations
      • Stock Info
        • Stock Quote
        • Stock Chart
        • Historical Stock Quote
        • Investment Calculator
      • Financials
        • SEC Filings
      • Governance
        • Executive Management
        • Board of Directors
        • Governance Documents
      • Resources
        • Investor FAQs
        • Information Request Form
        • Investor Contacts
        • Investor Email Alerts

Board of Directors

Board of Directors

Portrait

Frank L. Douglas, Ph.D., M.D., Chair, Governance Committee and Scientific Advisory Board

An award-winning industry veteran with more than three decades of experience in healthcare, pharmaceuticals, and entrepreneurship, Dr. Frank Douglas leads EOM’s clinical development team. He held leadership roles in both large and small biopharmaceutical companies, leading teams that were responsible for the development and marketing approval of many drugs, including Allegra®, Lantus®, Taxotere®, and Actone®.

Dr. Douglas has held several academic positions, including Professor of the Practice in the Massachusetts Institute of Technology (MIT) Sloan School of Management and similar appointments in the departments of Biology, Biological Engineering, and the Harvard-MIT Division of Health Sciences and Technology. He also was the founder and first executive director of the MIT Center for Biomedical Innovation and is the recipient of numerous prestigious awards, including being honored twice as the Global Pharmaceutical R&D Director of the Year.

Dr. Douglas holds a BS in Chemistry from Lehigh University, Ph.D. in Physical Chemistry, and a M.D. from Cornell University.

Portrait

Eli Goldberger, Founder, Chairman & COO

Eli Goldberger is EOM’s Founder, Chairman and Chief Operating Officer. Mr. Goldberger is a successful entrepreneur, focusing on advancing innovations in pharmaceuticals, women’s health, and energy.

Portrait

Irach Taraporewala, Ph.D., Chief Executive Officer & Director

Dr. Irach Taraporewala, EOM CEO and Director, has multiple accomplishments in drug discovery, development and delivery, formulation, medical devices, radiopharmaceuticals, DNA diagnostics, and regulatory affairs. His R&D contributions span several therapeutic areas, including ophthalmology, cancer, inflammation, immunology, endocrine, CNS, infectious disease, malaria, and cachexia. Dr. Taraporewala also was the founder, CEO, President, and Board member of OHR Pharmaceutical.

Portrait

Julie Kampf, Chair, Compensation Committee

Julie Kampf was elected to the Company’s board of directors in April 2022. Ms. Kampf is Chief Executive Officer of JBK Associates International, a global executive search firm which she founded in 2003. Prior thereto, she gained deep business knowledge in product development, marketing, sales, and organizational development, having started her 17-year career in the fashion industry as a Macy’s Executive Trainee, with a subsequent series of roles of increasing responsibility at Warnaco Inc, Hartmann Inc and Michael Stevens, LTD, ultimately rising to Sr. VP. She has served as a member of the board of directors of Marizyme, Inc., a publicly traded biotechnology company, since February 2021., and as a member of the board of directors of Jupiter Neurosciences, Inc. since September 2021.

Ms. Kampf also has extensive not-for-profit board and advisory committee experience having served on Howard University’s School of Communications Board of Visitors, where she helped launch an entrepreneurial incubator and established an award for student entrepreneurs. Her not-for-profit board service spans the Linkage Diversity Summit, Enterprising Women magazine, International Association of Corporate and Professional Recruitment, Girl Scout Council of Bergen County, Guiding Eyes for the Blind. Additionally, she has served on the Executive Committee of Good Grief, a national leader in delivering grief services to children and their families. Ms. Kampf earned a BA in Political Science from the University of Rhode Island, where she minored in Marketing.

Portrait

Robert W. Lehman , Chair, Audit Committee

Robert W. Lehman was elected to our Board of Directors in April 2022. From 1995 until his retirement in 2021, he was a partner at Ernst & Young, LLP where he served as the lead audit partner and quality review partner for dozens of SEC reporting companies. During the most recent ten years, he acted as that firm’s US Division and Market Leader for the East Coast Real Estate, Hospitality and Construction Practice. Mr. Lehman holds a B.A. in Accounting from Queens College of the City University of New York.

Contact Us

EOM PHARMACEUTICALS
136 Summit Ave., Suite 100
Montvale, NJ 07645

(201) 351-0605
info@eompharma.com


Quick Links

  • SEC Filings
  • Investor FAQs
  • Information Request Form
  • Join the Team

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At EOM Pharmaceuticals, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to EOM Pharmaceuticals to send you the requested Investor Email Alert updates.

* Required

*
Investor Alert Options
*





Unsubscribe

Email Alert Sign Up Confirmation

Company Logo
  • Terms & Conditions
© EOM Pharmaceuticals Holdings, Inc. All rights reserved.
Powered By Q4 Inc. 5.91.0.8 (opens in new window)